Mektovi (Binimetinib)

Binimetinib is a medicine used to treat melanoma and a type of lung cancer that have a change in a gene called BRAF. It is taken as a pill by mouth, together with another pill called encorafenib. It works by blocking a signal inside the cancer cells that tells them to grow.

Brand names:Mektovi
Medication

What people taking Mektovi (Binimetinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Mektovi (Binimetinib) for Melanoma?

NameHow it went

About Mektovi (Binimetinib)

What It's For

Binimetinib, sold as Mektovi, is a targeted cancer medicine taken by mouth. It is used only in combination with a second targeted pill, encorafenib (Braftovi), for two cancers that carry a specific change in a gene called BRAF: melanoma that has spread or cannot be removed with surgery, and non-small cell lung cancer that has spread, in adults. The gene change must be confirmed before treatment starts. For melanoma the eligible changes are called BRAF V600E and V600K; for lung cancer it is V600E. Testing is done on a tumor sample, and for lung cancer sometimes on a blood sample first. Cancers without one of these changes are not expected to respond, so the test result decides whether this pairing is an option at all.

How It Works

In healthy cells, a chain of proteins passes growth signals from the cell surface to the nucleus, switching on only when the cell needs to divide. A BRAF mutation jams one link in that chain in the on position, so the cancer cell keeps receiving a message to grow. Encorafenib blocks the faulty BRAF protein itself. Binimetinib blocks MEK, the next link further down the same chain. Hitting two points at once shuts the signal down more completely than either drug alone, and in laboratory and animal studies it also delayed the point at which cancer cells found a way around the blockade. That is why the two are prescribed as a pair rather than separately.

Dosage & Administration

Mektovi comes as 15 mg tablets. The usual dose is 45 mg (three tablets) twice a day, about 12 hours apart, with or without food. It is taken alongside encorafenib, which has its own once-daily schedule, and both continue for as long as the cancer stays controlled and side effects remain manageable. People with moderate or severe liver impairment start at a lower dose. If a dose is missed and the next one is less than 6 hours away, skip it and take the next dose on time. If you vomit after a dose, do not take an extra one; just continue with the next scheduled dose. The care team often pauses treatment or lowers the dose to manage side effects, so follow their current instructions rather than the starting dose. If encorafenib is stopped for good, binimetinib is stopped too.

Side Effects

Tiredness, nausea, diarrhea, vomiting and stomach pain are the most common side effects of the combination, and people treated for lung cancer also often report muscle and joint pain, constipation, rash, cough and breathlessness. Many of these can be eased with supportive medicines or a dose change, so they are worth raising early rather than enduring. Eye problems are a known effect of MEK inhibitors. The most common is fluid building up under the retina, which can blur or distort vision and often improves when the dose is paused. A blocked vein in the eye and inflammation inside the eye are rarer. Call the care team the same day for any change in vision, including sudden loss of sight; it should be checked by an eye specialist within 24 hours. Several other serious effects need prompt contact with the care team: shortness of breath, tiredness or swelling that could mean the heart is pumping less strongly; yellowing of the skin or eyes or dark urine, which can signal liver injury; new muscle weakness or pain with dark urine, a sign of muscle breakdown; unusual or prolonged bleeding; and a new or worsening cough, which can signal lung inflammation. Blood clots can also form. Get emergency care for sudden difficulty breathing, which can mean a clot has reached the lungs, and contact the team promptly about new pain or swelling in one leg.

Interactions & Warnings

Binimetinib itself has no known clinically important drug interactions, but its partner encorafenib does. Encorafenib speeds up the breakdown of many medicines and can make hormonal birth control (pills, patches, rings or implants) less reliable. It is also affected by grapefruit juice and by some antifungals and antibiotics, and can affect heart rhythm. Give the care team and pharmacist a full list of medicines and supplements before starting. Binimetinib can harm a developing baby. People who could become pregnant have a pregnancy test before starting and should use effective contraception during treatment and for 30 days after the last dose, using a non-hormonal method because encorafenib can make hormonal methods ineffective, and should tell the care team right away if pregnancy is suspected. Breastfeeding is not advised during treatment and for 2 weeks after the last dose of the combination (3 days after binimetinib, but 2 weeks after encorafenib). The combination can cause new cancers, most often new skin cancers. Skin checks are done before, during and after treatment, and any new growth or change in an existing mole should be reported promptly. Serious bleeding has occurred, including fatal bleeding in the brain in people whose cancer had spread there, so a history of bleeding problems or brain metastases is important to discuss. Safety has not been established in people whose heart already pumps weakly or who have had a blocked vein in the eye.

What to Expect

Treatment comes with a regular monitoring schedule. A heart scan (an echocardiogram or similar test measuring how well the heart pumps) is done before starting, after one month and then every 2 to 3 months. Liver blood tests are checked before starting and monthly, and a muscle enzyme test is checked periodically. Eye examinations happen at regular intervals, and the skin is checked for new growths. In the trials, most heart changes resolved, and eye changes rarely led to stopping treatment. Scans at intervals show whether the cancer is shrinking or holding steady. In the main melanoma trial, the combination kept the cancer from growing for a median of about 15 months, roughly twice as long as an older single BRAF drug (about 7 months), and people lived a median of about 34 months versus 17. In lung cancer, tumors shrank substantially in about three in four people who had not had earlier treatment and in about half of those who had; that study had no comparison group. These are group figures (half of people did better and half worse), and individual results vary widely. Treatment continues as long as it is working and tolerable. Many people need at least one dose pause or reduction along the way, which does not mean the treatment has failed. If the cancer grows again, the team discusses what other treatments are available.

Questions to Ask Your Doctor

  1. 1.How was my BRAF mutation confirmed, and how does this combination compare with immunotherapy for my situation?
  2. 2.What side effects should I report the same day, and who do I call outside office hours?
  3. 3.How often will I have heart scans, eye exams, blood tests and skin checks, and who arranges them?
  4. 4.Which of my current medicines or supplements, including birth control, could interact with encorafenib?
  5. 5.If side effects become hard to manage, how would we adjust the doses, and what are my options if the cancer grows?

Last reviewed • Oct 2026

Educational content, not medical advice.